A quick peek into the report
Table of Contents
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
1.3.1 Impact Analysis
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
1.6.1 Overview
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2.1 Chemotherapy
2.2 Peptide Receptor Radionuclide Therapy (PRRT)
2.3 Somatostatin Analogues
2.4 Targeted Therapies
3.1 Injectable
3.2 Intra Tumoral
3.3 Oral
4.1 North America
4.1.1 Market Dynamics
4.1.2 Market Sizing and Forecast
4.1.3 North America Gastroenteropancreatic Neuroendocrine Tumors Market, by Country ($Million), 2023-2035
4.1.3.1 U.S.
4.1.3.2 Canada
4.2 Europe
4.2.1 Market Dynamics
4.2.2 Market Sizing and Forecast
4.2.3 Europe Gastroenteropancreatic Neuroendocrine Tumors Market, by Country ($Million), 2023-2035
4.2.3.1 U.K.
4.2.3.2 France
4.2.3.3 Germany
4.2.3.4 Italy
4.2.3.5 Spain
4.2.3.6 Rest-of-Europe
4.3 Asia-Pacific
4.3.1 Market Dynamics
4.3.2 Market Sizing and Forecast
4.3.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumors Market, by Country ($Million), 2023-2035
4.3.3.1 Japan
4.3.3.2 China
4.3.3.3 India
4.3.3.4 Australia
4.3.3.5 South Korea
4.3.3.6 Rest-of-Asia-Pacific
4.4 Rest-of-the-World
4.4.1 Market Dynamics
4.4.2 Market Sizing and Forecast Rest-of-the-World Gastroenteropancreatic Neuroendocrine Tumors Market, by Type ($Million), 2023-2035
4.4.3 Rest-of-the-World Gastroenteropancreatic Neuroendocrine Tumors Market, by Country ($Million), 2023-2035
4.4.3.1 Latin America
4.4.3.2 Middle East and Africa
5.1 Competitive Landscape
5.1.1 Mergers and Acquisitions
5.1.2 Partnership, Alliances and Business Expansion
5.1.3 New Offerings
5.1.4 Regulatory Activities
5.1.5 Funding Activities
5.2 Company Profiles
5.2.1 Bristol Myers Squibb
5.2.1.1 Overview
5.2.1.2 Top Products / Product Portfolio
5.2.1.3 Top Competitors
5.2.1.4 Target Customers/End-Users
5.2.1.5 Key Personnel
5.2.1.6 Analyst View
5.2.2 Debiopharm
5.2.2.1 Overview
5.2.2.2 Top Products / Product Portfolio
5.2.2.3 Top Competitors
5.2.2.4 Target Customers/End-Users
5.2.2.5 Key Personnel
5.2.2.6 Analyst View
5.2.3 Eli Lilly and Company
5.2.3.1 Overview
5.2.3.2 Top Products / Product Portfolio
5.2.3.3 Top Competitors
5.2.3.4 Target Customers/End-Users
5.2.3.5 Key Personnel
5.2.3.6 Analyst View
5.2.4 F.Hoffmann-La Roche
5.2.4.1 Overview
5.2.4.2 Top Products / Product Portfolio
5.2.4.3 Top Competitors
5.2.4.4 Target Customers/End-Users
5.2.4.5 Key Personnel
5.2.4.6 Analyst View
5.2.5 HUTCHMED
5.2.5.1 Overview
5.2.5.2 Top Products / Product Portfolio
5.2.5.3 Top Competitors
5.2.5.4 Target Customers/End-Users
5.2.5.5 Key Personnel
5.2.5.6 Analyst View
5.2.6 Ipsen
5.2.6.1 Overview
5.2.6.2 Top Products / Product Portfolio
5.2.6.3 Top Competitors
5.2.6.4 Target Customers/End-Users
5.2.6.5 Key Personnel
5.2.6.6 Analyst View
5.2.7 Merck & Co.
5.2.7.1 Overview
5.2.7.2 Top Products / Product Portfolio
5.2.7.3 Top Competitors
5.2.7.4 Target Customers/End-Users
5.2.7.5 Key Personnel
5.2.7.6 Analyst View
5.2.8 Novartis AG
5.2.8.1 Overview
5.2.8.2 Top Products / Product Portfolio
5.2.8.3 Top Competitors
5.2.8.4 Target Customers/End-Users
5.2.8.5 Key Personnel
5.2.8.6 Analyst View
5.2.9 Orano Med
5.2.9.1 Overview
5.2.9.2 Top Products / Product Portfolio
5.2.9.3 Top Competitors
5.2.9.4 Target Customers/End-Users
5.2.9.5 Key Personnel
5.2.9.6 Analyst View
5.2.10 Trio Medicines Ltd
5.2.10.1 Overview
5.2.10.2 Top Products / Product Portfolio
5.2.10.3 Top Competitors
5.2.10.4 Target Customers/End-Users
5.2.10.5 Key Personnel
5.2.10.6 Analyst View
5.2.11 Others
Table: Global Gastroenteropancreatic Neuroendocrine Tumors Market (by Drug Class), $Million, 2023-2035
Table: Global Gastroenteropancreatic Neuroendocrine Tumors Market (by Route of Administration), $Million, 2023-2035
Table: Global Gastroenteropancreatic Neuroendocrine Tumors Market (by Region), $Million, 2023-2035
Figure: Global Gastroenteropancreatic Neuroendocrine Tumors Market Coverage
Figure: Global Gastroenteropancreatic Neuroendocrine Tumors Market Key Trends, Impact Analysis, 2023-2035
Gastroenteropancreatic Neuroendocrine Tumors Market Report Coverage
|
Gastroenteropancreatic Neuroendocrine Tumors Market |
|||
|
Base Year |
2024 |
Market Size in 2024 |
$XX Billion |
|
Forecast Period |
2025-2035 |
Value Projection and Estimation by 2035 |
$XX Billion |
|
CAGR During Forecast Period |
XX% |
|
|
Some prominent names established in this market are:
• Bristol Myers Squibb
• Debiopharm
• Eli Lilly and Company
• F.Hoffmann-La Roche
• HUTCHMED
• Ipsen
• Merck & Co.
• Novartis AG
• Orano Med
• Trio Medicines Ltd
How can this report add value to an organization?
Product/Innovation Strategy: This report provides a comprehensive product/innovation strategy for the Gastroenteropancreatic Neuroendocrine Tumors Market, identifying opportunities for market entry, technology adoption, and sustainable growth. It offers actionable insights, helping organizations to meet environmental standards, gain a competitive edge, and capitalize on the increasing demand for eco-friendly solutions in various industries.
Growth/Marketing Strategy: This report offers a comprehensive growth and marketing strategy designed specifically for the Gastroenteropancreatic Neuroendocrine Tumors Market. It presents a targeted approach to identifying specialized market segments, establishing a competitive advantage, and implementing creative marketing initiatives aimed at optimizing market share and financial performance. By harnessing these strategic recommendations, organizations can elevate their market presence, seize emerging prospects, and efficiently propel revenue expansion.
Competitive Strategy: This report crafts a strong competitive strategy tailored to the Gastroenteropancreatic Neuroendocrine Tumors Market. It evaluates market rivals, suggests methods to stand out, and offers guidance for maintaining a competitive edge. By adhering to these strategic directives, companies can position themselves effectively in the face of market competition, ensuring sustained prosperity and profitability.
Global Gastroenteropancreatic Neuroendocrine Tumors Market, Analysis and Forecast: 2025-2035
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors originating in the gastrointestinal tract or pancreas, arising from hormone-producing endocrine cells. These tumors can be functional or non-functional and are often diagnosed at later stages due to their nonspecific symptoms. Treatment typically involves surgery, medical therapies, and, in some cases, radiotherapy or targeted therapies. The market for GEP-NETs is growing due to advancements in diagnostics and treatment options.
The growth of the GEP-NETs market is driven by the increasing incidence of these tumors, better detection through advanced diagnostics, and rising awareness. The aging population and greater access to healthcare are fuelling demand for treatments. The approval of novel therapies such as peptide receptor radionuclide therapy (PRRT) and the expansion of research and development are further accelerating market growth.
The GEP-NETs market faces challenges such as high treatment costs, which can limit patient access, and complex diagnostic procedures, often leading to late-stage diagnoses. Additionally, the rarity of these tumors results in limited clinical expertise, particularly in underserved regions. Regulatory hurdles also slow the approval of new treatments, impeding timely access to novel therapies.
Recent advancements in GEP-NETs treatment include the introduction of targeted therapies such as PRRT, which uses radiolabeled somatostatin analogs, improving treatment efficacy and minimizing side effects. New drug candidates, including somatostatin analogs and tyrosine kinase inhibitors, are under development. Additionally, immunotherapies are showing potential, with clinical trials exploring their role in GEP-NETs treatment.
The GEP-NETs market is competitive, with major players such as Ipsen, Novartis, and Roche leading with approved therapies such as somatuline and sandostatin. Emerging biotech companies are developing next-generation therapies, such as PRRT and immunotherapies. Collaborations between industry players and research institutions are common, focusing on personalized medicine and biomarker-driven treatments to address specific patient needs.
Market Segmentation:
Segmentation 1: by Drug Class
• Chemotherapy
• Peptide Receptor Radionuclide Therapy (PRRT)
• Somatostatin Analogues
• Targeted Therapies
Segmentation 2: by Route of Administration
• Injectable
• Intra tumoral
• Oral
Segmentation 3: by the Region
• North America
• Europe
• Asia-Pacific
The global gastroenteropancreatic neuroendocrine tumors (GEP-NETs) market is experiencing robust growth, propelled by several key drivers. Firstly, the increasing global incidence of GEP-NETs, with over 12,000 new cases reported annually in the U.S. alone, has heightened the demand for effective treatment options. Secondly, advancements in diagnostic technologies, such as Gallium-68 DOTATATE PET/CT scans, have enabled earlier and more accurate detection of these tumors, facilitating timely intervention. Thirdly, the development and approval of novel therapies, including peptide receptor radionuclide therapy (PRRT) with lutathera, have expanded treatment options, offering improved efficacy and reduced side effects. Additionally, increasing awareness among healthcare professionals and patients has led to more diagnoses and, consequently, a greater need for therapeutic solutions. Furthermore, the rise in research and development activities, supported by both public and private sectors, is accelerating the discovery of new treatment modalities and biomarkers, further driving market expansion.
Gastroenteropancreatic Neuroendocrine Tumors Market - A Global and Regional Analysis
Focus on Drug Class, Route of Administration, and Region - Analysis and Forecast, 2025-2035
This report will be delivered in 7-10 working days.
Frequently Asked Questions
The global gastroenteropancreatic neuroendocrine tumors market is led by prominent pharmaceutical companies such as Bristol Myers Squibb, Debiopharm, Eli Lilly and Company, F.Hoffmann-La Roche, HUTCHMED, Ipsen, Merck & Co., Novartis AG, Orano Med and Trio Medicines Ltd.
Trends:
• Increasing incidence and awareness
• Advancements in diagnostic technologies
• Emergence of targeted therapies
• Personalized medicine approaches
Driver:
• Rising global incidence of GEP-NETs
• Technological advancements in treatment modalities
• Increased research and development investments
• Growing healthcare expenditure in emerging markets
• Regulatory approvals of new therapies
• High treatment costs
• Diagnostic complexities
• Regulatory and approval delays
• Limited availability of targeted therapies
• Lack of standardized treatment protocols
• Advancements in targeted therapies
• Expansion of clinical applications
• Integration of artificial intelligence (AI) in diagnostics and treatment planning
• Development of novel drug delivery systems
• Expansion of healthcare infrastructure in emerging markets